



**Dr. Timothy Wells** has been the Chief Scientific Officer of Medicines for Malaria Venture (MMV) since 2007, building and managing a portfolio of new medicines from discovery through to post-approval studies. In collaboration with a wide network of partners, MMV has launched 8 products over this period, which are used to treat millions of children annually. In the last decade, MMV has managed a transformation of the antimalarial drug pipeline, driven by identification of new targets and inhibitors coming from high content screening, but also structure-based design. These new generation compounds are now in phase II studies, where MMV has built up strengths in combination sciences and experimental medicine to help identify the best new combination therapies to move into pivotal trials.

Prior to joining MMV, he had over 20 years experience in drug discovery and development. From 1997 to 2006, he was the Head of Research for the Swiss biotech company Serono, discovering and developing new small molecule and protein products now approved for Merkel-cell carcinoma. He a non-executive director at Kymab, with a personal interest in applying antibody technology in infectious disease. He received his PhD in Chemistry in 1987, on engineering enzyme transition states with Professor Sir Alan Fersht at Imperial College, London; and his ScD in Biology in 2009, from Cambridge University in the UK, for work on cytokine biology. He is a fellow of the UK's Royal Society of Chemistry and Academy of Medical Sciences.